What is it about?
We investigated rt-PA efficacy as a function of clot size, rt-PA concentration, combination of rt-PA with heparin, and clot age. The study has brought novel insights into mechanisms of rt-PA limitations using a single model based on clots prepared out of human blood. Further, it provided implications for observed clinical phenomena concerning treatment of the ischemic stroke.
Featured Image
Why is it important?
Insights into the pharmacological treatment of stroke and interactions between medications and relevant factors.
Perspectives
rTPA is used to thrombolyse arterial clots in stroke patients. This study looks at how clot size, clot age and pre-heparinization effect the efficacy of Alteplase.
Mr Sumeet Gulati
International Clinical Research Center, St. Anne’s University Hospital Brno, Pekarska 53, 656 91, Brno, Czech Republic
The study provides cues for new thrombolytics design.
Jan Víteček
Institute of Biophysics of the CAS, v. v. i.
Read the Original
This page is a summary of: Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment, PLOS One, June 2024, PLOS,
DOI: 10.1371/journal.pone.0302269.
You can read the full text:
Contributors
The following have contributed to this page
